What is Coherus BioSciences Inc (CHRS) stock price today?

Coherus BioSciences Inc (CHRS) currently trades at $1.74 per share. The stock has a market capitalization of $262.31M and a P/E ratio of —x.

Is CHRS stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Coherus BioSciences Inc has a Smart Value Score of 47/100 (Grade C), resulting in a "Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Coherus BioSciences Inc's revenue and earnings?

Coherus BioSciences Inc has trailing twelve-month (TTM) revenue of $42.17M with profit margins of 398.40%. Earnings per share (EPS) is $-1.56.

CHRS

Coherus BioSciences Inc

NASDAQ: CHRS · HEALTHCARE · BIOTECHNOLOGY

$1.74

-1.69% today

Updated 2026-04-29

Market cap

$262.31M

P/E ratio

—

P/S ratio

6.22x

EPS (TTM)

$-1.56

Dividend yield

—

52W range

$1 – $3

Volume

1.3M

Market cap

$262.31M

P/E ratio

—

P/S ratio

6.22x

EPS (TTM)

$-1.56

Dividend yield

—

52W range

$1 – $3

Volume

1.3M

WallStSmart proprietary scores

out of 100

Grade: C

Sell

Investment rating

4.7

Growth

5.0

Quality

C+

6.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$6.75

+287.93%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Profit margin 398.40% — above average

+ ROE 33.10% — strong efficiency

+ Revenue growth 64.90% QoQ

Risks

- Negative free cash flow $-19.72M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$211.04M	$257.24M	$266.96M	$42.17M	$42.17M
Net income	$-291.75M	$-237.89M	$28.51M	$-170.29M	$-37.64M
EPS	—	—	—	—	$-1.56
Free cash flow	$-243.16M	$-175.17M	$-20.44M	$-138.51M	$-19.72M
Profit margin	-138.24%	-92.48%	10.68%	-403.80%	398.40%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-01-23	LANFEAR, DENNIS M	Buy	750,000	—
2026-01-23	LANFEAR, DENNIS M	Buy	375,000	—
2026-01-22	MCMICHAEL, BRYAN J	Buy	225,000	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
CHRS	$262.31M	47	4.7	6.0	5.0	5.0	—	Hold
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Coherus BioSciences Inc trades at $1.74. Our Smart Value Score of 47/100 indicates the stock is fair. TTM revenue stands at $42.17M. with profit margins at 398.40%.

Frequently asked questions

What is Coherus BioSciences Inc's stock price?

Coherus BioSciences Inc (CHRS) trades at $1.74.

Is Coherus BioSciences Inc overvalued?

Smart Value Score 47/100 (Grade C, Sell).

What is the price target of Coherus BioSciences Inc (CHRS)?

The analyst target price is $6.75, representing +287.9% upside from the current price of $1.74.

What is Coherus BioSciences Inc's revenue?

TTM revenue is $42.17M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio6.22x

ROE33.10%

Beta1.04

50D MA$1.72

200D MA$1.49

Shares out0.15B

Float0.13B

Short ratio—

Avg volume1.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

CHRS vs LLY →CHRS vs JNJ →CHRS vs ABBV →Stock screener →